Publications by authors named "Victoria Nachar"

Claim this Profile
C
Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma.
Meng-Hsuan Lin, Jonathan Weiss, Tycel J Phillips, Dahlia Sano, Shannon A Carty, Victoria R Nachar

Leuk Lymphoma· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.
Brian Hess, Alison Moskowitz, James A Davis, Paolo Strati, Yazeed Sawalha, Victoria Nachar

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Implementation of Oral Anticancer Agent Tools for a Thematic Quality Improvement Program: A Collaboration Between Hematology Oncology Pharmacist Association and ASCO Quality Training Program.
Victoria Nachar, Marjorie Adams Curry, Diana Kostoff, Angela Wood, Karen B Farris

JCO Oncol Pract· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma.
James A Davis, Jordan Snyder, Mikhaila Rice, Donald C Moore, Christopher Cahoon, Victoria R Nachar

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis.
Christy J Khouderchah, Madeleine Ochs, Matthew Pianko, Zahra Mahmoudjafari, Jordan Snyder, Victoria R Nachar

J Oncol Pharm Pract· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination.
Zahra Mahmoudjafari, Amir Ali, James Davis, Tyler Sandahl, Victoria Nachar

J Adv Pract Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Victoria Nachar

Blood· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
James A Davis, Katelynn Granger, Alex Sakowski, Sara Goodwin, Amanda Herbst, Victoria R Nachar

Expert Rev Hematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma.
Victoria R Nachar, Anthony J Perissinotti, Bernard L Marini, Yasmin H Karimi, Tycel J Phillips

Ann Hematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.
Tycel J Phillips, David Bond, Radihka Takiar, Karson Kump, Malalthi Kandarpa, Victoria Nachar

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma.
Anisa Bici, Matthew J Pianko, Victoria R Nachar

Leuk Lymphoma· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.
Elizabeth A Griffiths, Vivek Roy, Laura Alwan, Kimo Bachiashvili, John Baird, Victoria Nachar

J Natl Compr Canc Netw· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective.
Jacqueline C Dela-Pena, Madeleine A King, Julia Brown, Victoria R Nachar

J Oncol Pharm Pract· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma.
Grace T Baek, Noah J Mathis, Anthony J Perissinotti, Bernard L Marini, Anna Brown, Victoria R Nachar

Leuk Lymphoma· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation and outcomes of a pharmacist-led collaborative drug therapy management program for oncology symptom management.
Morgan J Homan, Justin H Reid, Victoria R Nachar, Lydia L Benitez, Anna M Brown

Support Care Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to Choose An Appropriate Anticoagulant for Cancer-Associated Thrombosis.
Jordan K Schaefer, Amro Elshoury, Victoria R Nachar, Michael B Streiff, Ming Y Lim

J Natl Compr Canc Netw· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy Remote Care Monitoring Program: Integration of SMS Text Patient-Reported Outcomes in the Electronic Health Record and Pharmacist Intervention for Chemotherapy-Induced Nausea and Vomiting.
Shannon Hough, Rachel McDevitt, Victoria R Nachar, Shawna Kraft, Anna Brown

JCO Oncol Pract· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non-Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases.
Andrew H Tam, Allison J Schepers, Angel Qin, Victoria R Nachar

Ann Pharmacother· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical controversies in the treatment of cancer-associated venous thromboembolism.
Victoria R Nachar, Allison J Schepers

J Oncol Pharm Pract· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Brian G Bazzell, Lydia L Benitez, Bernard L Marini, Anthony J Perissinotti, Tycel J Phillips, Victoria R Nachar

Clin Lymphoma Myeloma Leuk· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma.
Adam C Robinson, Victoria R Nachar

J Oncol Pharm Pract· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas.
Taylor M Weis, Bernard L Marini, Victoria R Nachar, Anna M Brown, Tycel J Phillips

Leuk Lymphoma· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma.
Justin H Reid, Bernard L Marini, Victoria R Nachar, Anna M Brown, Sumana Devata

Crit Rev Oncol Hematol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.
Emily Hoylman, Anna Brown, Anthony J Perissinotti, Bernard L Marini, Matthew Pianko, Victoria R Nachar

Leuk Lymphoma· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosing Vincristine in Dose-Adjusted EPOCH-R: To Cap or Not to Cap?
Taylor M Weis, Anthony J Perissinotti, Victoria R Nachar, Anna M Brown, Tycel J Phillips

J Clin Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis